From the Journals

In young MCL patients, optimal treatment may vary

Publish date: May 4, 2018

 

FROM BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY


Dr. Rule reported consulting for Pharmacyclics, Napp, Sunesis, Acerta Pharma, Kite, AstraZeneca, Roche, Janssen, and Celgene, and research funding from Janssen, Celgene, and GSK. Dr. McCulloch reported having no financial disclosures.

SOURCE: McCulloch R et al. Best Pract Res Clin Haematol. 2018 Mar;31(1):90-8.

Pages

Recommended Reading

BTK inhibitor zanubrutinib active in non-Hodgkin lymphomas
MDedge Hematology and Oncology
VcR-CVAD yields high responses, ‘excellent’ survival in MCL
MDedge Hematology and Oncology
Triple therapy ups response in refractory mantle cell lymphoma
MDedge Hematology and Oncology
NF-kappaB pathway could help solve resistance problem in mantle cell lymphoma
MDedge Hematology and Oncology
Acalabrutinib shows less off-target activity in mantle cell lymphoma
MDedge Hematology and Oncology
Ibrutinib linked to invasive fungal infections
MDedge Hematology and Oncology
Outpatient CAR T infusions feasible using liso-cel
MDedge Hematology and Oncology
Time to rethink MCL treatment, trial design
MDedge Hematology and Oncology
Ibrutinib plus venetoclax is active in mantle cell lymphoma
MDedge Hematology and Oncology
PDPK1 could be novel target in MCL
MDedge Hematology and Oncology